1. Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial
- Author
-
Jonathan Corren, David Larson, Matthew C. Altman, R. Max Segnitz, Pedro C. Avila, Paul A. Greenberger, Fuad Baroody, Mark H. Moss, Harold Nelson, Allison J. Burbank, Michelle L. Hernandez, David Peden, Sarbjit Saini, Stephen Tilles, Iftikhar Hussain, Don Whitehouse, Tielin Qin, Miguel Villarreal, Michelle Sever, Lisa M. Wheatley, Gerald T. Nepom, and Srinath Sanda
- Subjects
Immunology ,Immunology and Allergy - Abstract
Thymic stromal lymphopoietin (TSLP) has been shown to play a central role in the initiation and persistence of allergic responses.We evaluated whether tezepelumab, a human monoclonal anti-TSLP antibody, improved the efficacy of subcutaneous allergen immunotherapy (SCIT) and promoted the development of tolerance in patients with allergic rhinitis.We conducted a double-blind parallel design trial in patients with cat allergy. A total of 121 patients were randomized to receive either intravenous tezepelumab plus subcutaneous cat SCIT, cat SCIT alone, tezepelumab alone, or placebo for 52 weeks, followed by 52 weeks of observation. Nasal allergen challenge (NAC), skin testing, and blood and nasal samples were obtained throughout the study.At week 52, the NAC-induced total nasal symptom scores (TNSS) (calculated as area under the curve [AUCInhibition of TSLP augments the efficacy of SCIT during therapy and may promote tolerance after a 1-year course of treatment. (ClinicalTrials.gov NCT02237196).
- Published
- 2023